Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study (INCAS)
Chronic Pulmonary Aspergillosis, Aspergillosis
About this trial
This is an interventional treatment trial for Chronic Pulmonary Aspergillosis focused on measuring immunotherapy, interferon gamma
Eligibility Criteria
Inclusion Criteria: Diagnosis of CPA Started antifungal treatment for CPA within the last 2 weeks and received no antifungals for CPA in the eight weeks prior Chest CT scan available within the 6 months prior to enrolment Individuals of child bearing potential agree to have pregnancy test an use highly effective contraception Exclusion Criteria: Moderate to severe liver dysfunction (Child-Pugh Class B or C) Renal failure (eGFR <30 mL/min) Clinically diagnosed active depression Active tuberculosis or non-tuberculous mycobacterial (NTM) lung disease Acute infection or other event within the preceding 4 weeks which, as assessed by the investigators, might interfere with the assessment of response to treatment Use of any interferon formulation within the preceding six months Active viral hepatitis infection Pregnancy or breastfeeding Immunosuppression (>15mg prednisolone/day for at least four weeks or equivalent) within the preceding six months Inability to self-administer subcutaneous medications AND lack of a carer who can administer Participants lacking capacity to consent
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Antifungal
Antifungal plus inteferon gamma
Any oral triazole antifungal as per routine care
Any oral triazole antifungal as per routine care plus interferon-gamma three times weekly subcutaneously 50 micrograms/m2 for 3 months